Phase 3 Recruiting Academic/Other
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal a…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT03150693
Sites in California: - Kaiser Permanente-Deer Valley Medical Center — Antioch, California
- PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
Phase 3 Recruiting NIH
This phase III trial compares the effectiveness of rituximab to mosunetuzumab in treating patients with follicular lymphoma with a low tumor burden. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06337318
Sites in California: - Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- City of Hope at Irvine Lennar — Irvine, California
- City of Hope Antelope Valley — Lancaster, California
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of geriatric evaluation and management with survivorship health education (GEM-S) to usual care on patient-reported physical function in older survivors of cancer. Survivorship care for older adults…
Sponsor: University of Rochester
NCT ID: NCT05006482
Sites in California: - Kaiser Permanente-Fremont — Fremont, California
- Kaiser Permanente-San Francisco — San Francisco, California
Phase 3 Recruiting Industry
The goal of this study is to evaluate nemtabrutinib compared with investigator's choice of ibrutinib or acalabrutinib in participants with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136559
Sites in California: - Alta Bates Summit Medical Center ( Site 0004) — Berkeley, California
- Moores Cancer Center ( Site 0003) — La Jolla, California
- Care Access - South Pasadena ( Site 0070) — Pasadena, California
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in California: - City of Hope (Adults and Pediatrics) — Duarte, California
- University of California San Diego Moores Cancer Center (Adults only) — La Jolla, California
- Loma Linda University Medical Center (Adults only) — Loma Linda, California
- Children's Hospital Los Angeles, Div. of Research Immunology/BMT (Adults and Pediatrics) — Los Angeles, California
- UCLA Medical Center (Adults and Pediatrics) — Los Angeles, California
Phase 3 Recruiting Industry
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell lymphoma (MCL). This study will also look at the safety of son…
Sponsor: BeOne Medicines
NCT ID: NCT06742996
Sites in California: - Ucsf Fresno — Fresno, California
- Kaiser Permanente Southern California — Irvine, California
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in California: - City of Hope Cancer Center — Duarte, California
- University of California San Diego Medical Center — La Jolla, California
- University of California Los Angeles — Los Angeles, California
- St. Joseph Hospital Center for Cancer Prevention and Treatment — Orange, California
- Stanford University Medical Center — Stanford, California
Phase 3 Recruiting Industry
The study is designed as a multicenter, randomized, open label Phase 3 study to compare the efficacy and safety of golcadomide in combination with rituximab vs investigator's choice in participants with relapsed/refractory follicular lymph…
Sponsor: Celgene
NCT ID: NCT06911502
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
- UCSF Helen Diller Medical Center at Parnassus Heights — San Francisco, California
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-16673 compared with investigator's choice (idelalisib plus rituximab \[for CLL only\] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in pa…
Sponsor: BeOne Medicines
NCT ID: NCT06846671
Sites in California: - UCLA Department of Medicine Hematologyoncology — Los Angeles, California
- Pih Health Whittier Hospital — Whittier, California
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treat…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091865
Sites in California: - David Geffen School of Medicine at UCLA — Los Angeles, California
- University of California Irvine Medical Center — Orange, California
- University of California (UC) Davis — Sacramento, California
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in California: - Alta Bates Summit Medical Center — Berkeley, California
- City of Hope Cancer Center — Duarte, California
- University of California Los Angeles (UCLA) - Cancer Care - Santa Monica — Santa Monica, California
Phase 3 Recruiting Industry
Part 1: This is a 5 Arm study primarily to determine the best dose out of the two dose levels of Belinostat and Pralatrexate combined with CHOP/COP in newly diagnosed PTCL patients based on Safety for part 2 study. Part 2 (Efficacy and Saf…
Sponsor: Acrotech Biopharma Inc.
NCT ID: NCT06072131
Sites in California: - University of California, San Francisco Fresno — Clovis, California
- University of California, Los Angeles Hem/ Onc Clinical Research Unit, Suite 600 — Santa Monica, California
Phase 3 Recruiting Academic/Other
RADAR is a multicentre, international, randomised, open-label phase III clinical trial composed of 2 trials running in parallel. Trial 1 will be led and sponsored by University College London (UCL) and conducted in Europe and Australia/New…
Sponsor: University College, London
NCT ID: NCT04685616
Sites in California: - Stanford University - (Stanford Cancer Institute) — Stanford, California
Phase 2 Recruiting NIH
This phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03739814
Sites in California: - PCR Oncology — Arroyo Grande, California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center — Burbank, California
- Community Cancer Institute — Clovis, California
- University Oncology Associates — Clovis, California
- City of Hope Comprehensive Cancer Center — Duarte, California
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in California: - Kaiser Permanente-Anaheim — Anaheim, California
- PCR Oncology — Arroyo Grande, California
- Kaiser Permanente-Bellflower — Bellflower, California
- Kaiser Permanente Downey Medical Center — Downey, California
- City of Hope Comprehensive Cancer Center — Duarte, California
Phase 2 Recruiting Network
This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma or CD22 positive B acute lymphoblastic leukemia that has come back (relapsed) or does not respond to treatment (ref…
Sponsor: Children's Oncology Group
NCT ID: NCT02981628
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- Loma Linda University Medical Center — Loma Linda, California
- Children's Hospital Los Angeles — Los Angeles, California
- Cedars-Sinai Medical Center — Los Angeles, California
Phase 2 Recruiting NIH
This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in California: - Kaiser Permanente Downey Medical Center — Downey, California
- Loma Linda University Medical Center — Loma Linda, California
- Miller Children's and Women's Hospital Long Beach — Long Beach, California
- Children's Hospital Los Angeles — Los Angeles, California
- Valley Children's Hospital — Madera, California
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL or SLL. The study will include a Phase 1 part to determine the recommended dose of JCAR017…
Sponsor: Juno Therapeutics, a Subsidiary of Celgene
NCT ID: NCT03331198
Sites in California: - City of Hope — Duarte, California
- City Of Hope — Duarte, California
- UC San Diego Moores Cancer Center — La Jolla, California
- University Of California San Diego Moores Cancer Center — La Jolla, California
- Local Institution - 0059 — Los Angeles, California
Phase 2 Recruiting NIH
This phase II trial compares mosunetuzumab to the usual treatment (rituximab) for improving survival in patients with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). Rituximab and mosunetuzumab are monoclonal antibodies. They bind…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05886036
Sites in California: - City of Hope Comprehensive Cancer Center — Duarte, California
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond…
Sponsor: Children's Oncology Group
NCT ID: NCT04870944
Sites in California: - Children's Hospital Los Angeles — Los Angeles, California
- Children's Hospital of Orange County — Orange, California
- UCSF Medical Center-Mission Bay — San Francisco, California
Phase 1, Phase 2 Recruiting Industry
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Sponsor: Sumitomo Pharma America, Inc.
NCT ID: NCT04988555
Sites in California: - Hoag Family Cancer Center — Newport Beach, California
- Stanford University — Palo Alto, California
Phase 2 Recruiting Industry
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-H…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06806033
Sites in California: - Community Cancer Institute (CCI) — Clovis, California
- Providence Medical Foundation — Fullerton, California
- Los Angeles Cancer Network — Glendale, California
- Valkyrie Clinical Trials — Los Angeles, California
- Valkyrie Clinical Trials — Panorama City, California
Phase 1, Phase 2 Recruiting Industry
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…
Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in California: - City of Hope — Duarte, California
- Providence St. John's Health Center — Santa Monica, California
- UCLA Department of Medicine - Hematology/Oncology — Santa Monica, California
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in California: - City of Hope — Duarte, California
- Children's Hospital Los Angeles — Los Angeles, California
- UCLA Mattel Children's Hospital — Los Angeles, California
- UCSF Benioff Children's Hospital Oakland — Oakland, California
- UCSF — San Francisco, California
Phase 2 Recruiting Industry
This is a Phase 2 global, multi-center, open-label study to assess the efficacy, safety and tolerability of Surovatamig (AZD0486) monotherapy in adult participants with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) who have receive…
Sponsor: AstraZeneca
NCT ID: NCT06526793
Sites in California: - Research Site — Duarte, California